CYP2D6 Genotype Not Found To Predict Tamoxifen Benefit In Breast Cancer
 

Two studies published in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer...

More...